The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.
about
Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancerBRCA1 reversion mutation acquired after treatment identified by liquid biopsy.Reverse the Resistance to PARP Inhibitors.Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action.Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing.Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer.Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics."Lazarus Response" to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion.RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA mutated breast cancer.Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation.The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and CancerBRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor ResistanceMethylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
P2860
Q33704050-557993D8-D9FC-4E6B-857E-75D118924908Q33869633-4896C790-FD3D-4BE4-BEF9-60A6CDB3EEEDQ37675896-2630894A-D537-411F-9322-5A9AF53DE707Q38725261-64C97DB3-0F91-45DB-A437-8BAF3D41757FQ41691425-2DE81BD1-75E0-4BF4-B81A-873B3F040245Q42315217-5DB8CE5F-03EB-4373-9B0C-4E6E08C84B6CQ47561562-B12EAC59-4E02-4D48-AE37-59E393BBBEC3Q48588785-296EEA22-FF4C-41C8-8D0F-24D4C4D0A1E0Q52564290-42B19961-8499-4F5A-9B11-8D28EE7136B0Q52590701-8397475B-87EF-4CCF-B0A8-00FF10968AF8Q52596087-1207A184-BA01-409E-8FF8-9B642F27896FQ52660676-A0772D4A-38DC-49E9-A419-BE8A8A084DF1Q55209617-22494F7B-2C0C-40F4-BF3A-5BDCFEA3190BQ55230708-D61E5B94-4FC9-4479-9266-DD02A2B63AC3Q57826033-C7559B06-9A2B-4696-8F98-866ED69F7FF7Q58696749-D374BA7E-7507-4395-8ED2-59594980A6F1Q59126243-BA4B3218-5CB5-4510-9784-FDB27BAF3083
P2860
The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The BRCA1-Δ11q Alternative Spl ...... PARP Inhibition and Cisplatin.
@en
type
label
The BRCA1-Δ11q Alternative Spl ...... PARP Inhibition and Cisplatin.
@en
prefLabel
The BRCA1-Δ11q Alternative Spl ...... PARP Inhibition and Cisplatin.
@en
P2093
P2860
P50
P1433
P1476
The BRCA1-Δ11q Alternative Spl ...... PARP Inhibition and Cisplatin.
@en
P2093
Alan D D'Andrea
Andrea J Bernhardy
Beth Karlan
Charlie Gourley
Cristina Cruz
Denise C Connolly
Elizabeth M Swisher
Emmanuelle Nicolas
Francisco J Candido Dos Reis
Geoffrey I Shapiro
P2860
P304
P356
10.1158/0008-5472.CAN-16-0186
P407
P50
P577
2016-05-01T00:00:00Z